“I am very encouraged that both clinicians and caregivers observed pervasiveimprovements across multiple, clinically important features of PMS…”
Like you Tin Shed Trader, I’m so happy for another group of patients that will benefit from this molecule eventually. In thinking about the much smaller number of GI issues in this trial, I’m hoping that Katelin and others like her, who are experiencing significant GI issues taking Daybue, may have the option to switch to NNZ-2591 in future if possible.
Raising a glass (again) today to Dame Margaret Brimble, along with Jon and the team and all fellow investors on this forum.
- Forums
- ASX - By Stock
- NEU
- Ann: P2 trial shows significant improvements in Phelan-McDermid
Ann: P2 trial shows significant improvements in Phelan-McDermid, page-46
-
-
- There are more pages in this discussion • 165 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NEU (ASX) to my watchlist
|
|||||
Last
$15.21 |
Change
-0.270(1.74%) |
Mkt cap ! $1.940B |
Open | High | Low | Value | Volume |
$15.20 | $15.33 | $15.02 | $3.938M | 259.3K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
8 | 272 | $15.21 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$15.22 | 659 | 17 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
11 | 474 | 15.220 |
7 | 662 | 15.210 |
11 | 837 | 15.200 |
6 | 564 | 15.190 |
5 | 1546 | 15.180 |
Price($) | Vol. | No. |
---|---|---|
15.230 | 494 | 15 |
15.240 | 887 | 9 |
15.250 | 1026 | 12 |
15.260 | 573 | 6 |
15.270 | 740 | 8 |
Last trade - 13.22pm 22/08/2024 (20 minute delay) ? |
Featured News
NEU (ASX) Chart |
The Watchlist
SS1
SUN SILVER LIMITED
Gerard O'Donovan, Executive Director
Gerard O'Donovan
Executive Director
SPONSORED BY The Market Online